SUNNYVALE, Calif., Sept. 10, 2019 /PRNewswire/ -- Accuray
Incorporated (NASDAQ: ARAY) announced today that the Geisinger
Medical Center radiation oncology team is first in Pennsylvania to treat cancer patients with the
innovative Radixact® System. The hospital, located in
Danville, is part of Geisinger
Health System, one of the United
States' most innovative health services organizations. The
system's speed, versatility and flexibility will enable the
clinical team to provide a treatment option for virtually any case
for which radiation therapy is prescribed, including large tumors
or multiple tumors throughout the body, hard-to-reach tumors, and
tumors that have recurred, including those in patients who may not
be candidates for retreatment with traditional delivery
systems.
Geisinger welcomed the Radixact System in a ribbon-cutting
ceremony led by the chairman of radiation oncology at Geisinger
Cancer Institute, Dr. Anand
Mahadevan. "The Radixact System will enable us to treat
patients with precision, speed and adaptability. The system's
unique architecture provides options for delivering radiation not
available with other devices and when combined with its advanced
software, will expand the types of tumors that may be effectively
treated with radiation, including craniospinal and total body
radiation with comfort and precision," said Dr. Mahadevan. "We look
forward to using the Radixact System to deliver the highest
standard of care to patients in central Pennsylvania and the surrounding area."
According to the Centers for Disease Control and
Prevention1, the state of Pennsylvania had the third highest incidence
rate of new cancers in the United
States in 2016, the most current year data were reported.
While the rate of new cancers diagnosed in the state remained
relatively stable between 2012 - 20161, the data
reinforce the need for innovative new treatment options that
successfully manage the disease while minimizing side effects and
their impact on quality of life.
The Radixact System was designed to improve patient care by
providing clinical teams with the tools they need to make the
planning and delivery of radiation straightforward, efficient and
effective for standard indications like breast and head and neck
cancers, and complex treatments such as total marrow
irradiation.
- The Radixact System delivers the same highly conformal and
homogeneous dose distribution faster than the previous TomoTherapy
platform, with a higher dose rate (1000 MU/minute) and imaging time
that is up to 66 percent faster. A combination of higher dose
output and faster image acquisition can shorten treatment times,
while improving the patient experience
- A fully-integrated, automated adaptive solution,
PreciseART® Adaptive Radiation Therapy Software, makes
adaptive radiotherapy simple and practical. The software enables
physicians to easily decide when adaptation of radiation delivery
during the course of treatment would be beneficial due to changes
in tumor size and patient anatomy
- The PreciseRTX® Retreatment Option accelerates and
automates the re-planning process to make re-treatment more
efficient for practices and more effective for patients in those
cases where, unfortunately, cancer has recurred and additional
radiation treatments are necessary
- The CTrue™ IR (Iterative Reconstruction) image guidance
software improves soft-tissue contrast and reduces noise, enhancing
image quality, while maintaining the same low imaging dose and fast
reconstruction time as earlier versions of the software. Patient
workflows are also more streamlined, facilitating the delivery of
precise treatments more quickly, for more patients
"We are excited to partner with the Geisinger Medical Center
team to help improve the lives of patients diagnosed with cancer,"
said Birgit Fleurent, chief
marketing officer at Accuray. "The Radixact System is intended to
administer radiation using a variety of delivery methods from
image-guided, intensity-modulated radiation therapy, TomoHelical™
rotational delivery mode and stereotactic body radiation therapy,
to TomoDirect™ non-rotational delivery mode and TomoEDGE™ dynamic
dose sculpting mode. This versatility provides the hospital's
clinical team with unprecedented flexibility and choice, enabling
them to offer a personalized and precise treatment approach that
truly addresses each patient's particular condition."
Important Safety Information
For Important
Safety Information please refer
to https://www.accuray.com/safety-statement.
About Accuray
Accuray Incorporated (Nasdaq: ARAY) develops, manufactures and
sells radiotherapy systems that are intended to make cancer
treatments shorter, safer, personalized and more effective,
ultimately enabling patients to live longer, better lives. Our
radiation treatment delivery systems in combination with
fully-integrated software solutions set the industry standard for
precision and cover the full range of radiation therapy and
radiosurgery procedures. For more information, please
visit www.accuray.com or follow us
on Facebook, LinkedIn, Twitter and YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to clinical applications,
clinical experiences and results, patient experiences, and patient
outcomes. These forward-looking statements involve risks and
uncertainties. If any of these risks or uncertainties materialize,
or if any of the company's assumptions prove incorrect, actual
results could differ materially from the results expressed or
implied by these forward-looking statements. These risks and
uncertainties include, but are not limited to, the company's
ability to achieve widespread market acceptance of its products;
the company's ability to develop new products or improve existing
products to meet customers' needs; the company's limited long-term
clinical data supporting the safety and efficacy of its products
and such other risks identified under the heading "Risk Factors" in
the company's annual report on Form 10-K, filed with the Securities
and Exchange Commission (the "SEC") on August 23, 2019 and as updated periodically with
the company's other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Media Contacts
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
bkaplan@accuray.com
Jayme Maniatis
MSLGROUP
+1 (781) 684-6610
accuray@mslgroup.com
______________________________________
1 U.S. Cancer Statistics Working Group. U.S. Cancer
Statistics Data Visualizations Tool, based on November 2018 submission data (1999-2016): U.S.
Department of Health and Human Services, Centers for Disease
Control and Prevention and National Cancer Institute;
www.cdc.gov/cancer/dataviz, June
2019
View original content to download
multimedia:http://www.prnewswire.com/news-releases/geisinger-medical-center-is-first-in-pennsylvania-to-treat-cancer-patients-with-accuray-radixact-system-300914464.html
SOURCE Accuray Incorporated